Mike Hollan

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical and electronics industries.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

The company announced a new CFO along with the creation of a new role, chief medical officer.

The survey also suggests that Medicaid is broadly popular amongst all Americans, regardless of political affiliation.

Hyfe’s CEO discusses the importance of DTx and how it can change the way certain conditions are treated.

Family caregivers with both children and elderly family members to care for are reporting higher levels of burnout and mental health issues.

Muscle loss is a serious issue for a number of patients, including those on GLP-1s.

The I LUVY YA for The Long Haul campaign features stories about the emotional impact of the disease.

The line-up consists of supplements to meet the health needs to patients taking GLP-1 medications for weight loss.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.

Charles River Laboratories will work directly with the platform.

The platform can reportedly outperform traditional methods.

LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.

The Healthwell Foundation published research that questioned over 1,500 Americans about their healthcare status.

The new product will allow for improved mRNA production with reduced costs.

The potential vaccine is being developed in partnership with the Cleveland Clinic and the NCI.

The biotech won the award for its work in obesity and inflammation treatment.

Research also showed that the test has a very low false positive rate.

The pharmaceutical company had previously been subjected to a 2-year suspension.

HCSC will take ownership of multiple businesses, allowing Cigna to refocus its efforts.

Pharma companies face unique challenges with market access in this region.

The two organizations will work together to promote healthy choices, such as early screenings.

Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline.

The Project Farma president discusses various ways the tariffs could impact the industry and how businesses can prepare or react.

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in pharma investing.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

A look at the current landscape and how young companies can set the stage for product launch.

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

The prospective study reportedly showed an improvement of over 10%.